|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Aprea Therapeutics, Inc. (APRE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
20,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, a mutated gene in cancer. Co.'s main product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Co. is conducting several trials in hematologic malignancy indications, including a trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
16,730 |
16,730 |
26,827 |
114,327 |
Total Buy Value |
$121,961 |
$121,961 |
$158,917 |
$218,541 |
Total People Bought |
4 |
4 |
4 |
5 |
Total Buy Transactions |
4 |
4 |
6 |
8 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Attar Eyal C. |
SVP, Chief Medical Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
108,000 |
108,000 |
|
- |
|
Schade Christian S |
Chairman & CEO |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
165,500 |
176,660 |
|
- |
|
Korbel Gregory Alan |
VP of Business Devt |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,500 |
|
- |
|
Abrahmsen Lars B. |
SVP, Chief Scientific Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
19,000 |
|
- |
|
Coiante Scott M |
SVP, Chief Financial Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
96,500 |
99,000 |
|
- |
|
Wessels Gregory S. |
SVP, Chief Commercial Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
Green Jeremy |
10% Owner |
|
2020-12-28 |
4 |
S |
$5.58 |
$2,791,290 |
I/I |
(500,000) |
1,768,718 |
|
- |
|
Rocklage Scott M |
Former 10% holder |
|
2020-10-05 |
4 |
S |
$25.30 |
$4,427,500 |
I/I |
(175,000) |
138,497 |
|
- |
|
Kcif Co-Investment Fund Kb |
10% Owner |
|
2020-07-07 |
4 |
S |
$34.55 |
$8,350,839 |
I/I |
(241,703) |
1,992,586 |
|
- |
|
Parmar Kush |
10% Owner |
|
2020-06-16 |
4 |
S |
$33.30 |
$4,662,000 |
I/I |
(140,000) |
313,497 |
|
- |
|
Rocklage Scott M |
Director |
|
2020-06-16 |
4 |
S |
$33.30 |
$4,001,461 |
I/I |
(120,164) |
75,965 |
|
- |
|
Rocklage Scott M |
Director |
|
2020-06-11 |
4 |
S |
$28.75 |
$7,044,412 |
I/I |
(245,000) |
80,772 |
|
- |
|
Parmar Kush |
10% Owner |
|
2020-06-11 |
4 |
S |
$28.75 |
$7,044,412 |
I/I |
(245,000) |
80,772 |
|
- |
|
Rocklage Scott M |
Director |
|
2020-05-19 |
4 |
S |
$35.15 |
$8,963,250 |
I/I |
(255,000) |
90,572 |
|
- |
|
Parmar Kush |
10% Owner |
|
2020-05-19 |
4 |
S |
$35.15 |
$8,963,250 |
I/I |
(255,000) |
90,572 |
|
- |
|
Versant Vantage I Gp-Gp, Llc |
10% Owner |
|
2020-05-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,484) |
0 |
|
- |
|
Versant Vantage I Gp-Gp, Llc |
10% Owner |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
3,484 |
1,734 |
|
- |
|
Versant Vantage I Gp-Gp, Llc |
10% Owner |
|
2020-05-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(116,664) |
216,669 |
|
- |
|
Versant Ventures V (canada), L.p. |
10% Owner |
|
2020-05-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(899,369) |
0 |
|
- |
|
Versant Ventures V (canada), L.p. |
10% Owner |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,606 |
1,178 |
|
- |
|
Kcif Co-Investment Fund Kb |
10% Owner |
|
2020-04-13 |
4 |
S |
$31.25 |
$6,579,625 |
I/I |
(210,548) |
2,234,289 |
|
- |
|
Versant Ventures V (canada), L.p. |
10% Owner |
|
2020-04-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,519,323 |
168,263 |
|
- |
|
Versant Ventures V (canada), L.p. |
10% Owner |
|
2020-04-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,519,323) |
0 |
|
- |
|
Parmar Kush |
10% Owner |
|
2019-10-07 |
4 |
B |
$15.00 |
$4,999,995 |
I/I |
333,333 |
333,333 |
1.5 |
- |
|
Parmar Kush |
10% Owner |
|
2019-10-07 |
4 |
A |
$0.00 |
$0 |
I/I |
2,506,650 |
100,772 |
|
- |
|
126 Records found
|
|
Page 4 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|